C4 Therapeutics, Inc. filings document the regulatory record for a clinical-stage biopharmaceutical company focused on targeted protein degradation and oncology drug development. Its 8-K reports cover material agreements, including the Roche research collaboration and license agreement for degrader-antibody conjugates, clinical and regulatory disclosures, operating results, business updates, and capital-structure matters involving common stock sales arrangements.
Proxy and governance filings describe board matters, executive compensation, equity awards, shareholder voting items, and by-law provisions, including forum-selection amendments. The filing record also includes Regulation FD disclosures, clinical presentation exhibits for cemsidomide, and other material-event reports tied to the company’s pipeline, collaborations, and public-company governance.
C4 Therapeutics, Inc. entered into a major research collaboration and license agreement with Roche to discover, develop and commercialize degrader‑antibody conjugates (DACs) for oncology. C4T grants Roche a worldwide, exclusive license for DACs against two undisclosed cancer targets, while Roche funds all development, regulatory, manufacturing and commercialization activities.
C4T will receive a $20.0 million upfront cash payment and is eligible for over $1.0 billion in development, regulatory and commercial milestone payments, plus tiered royalties ranging from mid‑single digit to low‑double digit percent on net sales. Roche also holds an option, for an additional fee, to add a third oncology target with its own milestones and royalties. The agreement can be terminated for customary reasons, and Roche may also terminate for convenience with 90 days’ notice.
Anderson Kenneth Carl reported acquisition or exercise transactions in this Form 4 filing.
C4 Therapeutics director Kenneth Carl Anderson received a grant of 4,259 shares of common stock of C4 Therapeutics, Inc. as compensation for his services as a non-employee director, in lieu of cash fees. The grant was valued at $2.70 per share, based on the closing market price on April 1, 2026. Following this award, he holds 68,230 shares directly, and additional shares are held indirectly through several irrevocable and revocable trusts, for which he disclaims beneficial ownership except to the extent of his pecuniary interest.
GROGAN DONNA ROY reported acquisition or exercise transactions in this Form 4 filing.
C4 Therapeutics director Donna Roy Grogan received 5,370 shares of common stock as compensation. The shares were issued under the company’s Non-Employee Director Compensation Policy, where she elected stock instead of cash fees for board service.
The value was based on the closing market price of $2.70 per share on April 1, 2026. After this grant, she directly holds 71,512 shares of C4 Therapeutics common stock.
CCCC submitted a Form 144 notice for the proposed sale of 101,175 shares of common stock via a stock option exercise to be effected on 03/09/2026. The filing also records a prior sale of 11,517 shares on 02/17/2026 with proceeds shown as $21,193.82.
C4 Therapeutics is a clinical-stage biopharmaceutical company focused on targeted protein degradation, using its proprietary TORPEDO platform to design small‑molecule degraders. Its lead programs are cemsidomide for multiple myeloma and CFT8919 for EGFR L858R‑mutant non‑small cell lung cancer, both orally bioavailable oncology candidates.
The company is extending its pipeline into inflammation, neuroinflammation and neurodegeneration, including CNS‑penetrant degraders. It relies heavily on third‑party manufacturers and strategic collaborations with Roche, Biogen, Merck KGaA, Betta Pharma and Pfizer. C4 reported net losses of $105.0 million in 2025 and $105.3 million in 2024 and expects to incur losses for several years, requiring substantial additional funding.
C4 Therapeutics reported fourth quarter and full-year 2025 results and outlined progress across its pipeline. Total revenue was $11.0 million for Q4 and $35.9 million for 2025, roughly flat year over year, while operating expenses declined modestly.
Full-year R&D was $104.2 million and G&A was $36.2 million, contributing to a net loss of $105.0 million, or $1.27 per share. Cash, cash equivalents and marketable securities were $297.1 million as of December 31, 2025, and the company expects this to fund its operating plan to the end of 2028. Strategically, cemsidomide advanced into a Phase 2 trial in later-line multiple myeloma, a Phase 1b combination study with elranatamab is expected to start in Q2 2026, C4T earned a $2 million milestone from Biogen for BTK degrader BIIB145, and it raised $125 million in an October 2025 equity offering.
C4 Therapeutics Chief Business Officer Scott N. Boyle reported equity compensation activity in C4 Therapeutics, Inc. common stock. On February 13, 2026, he received a grant of 200,000 restricted stock units (RSUs), with 100,000 RSUs vesting in three equal annual installments starting February 13, 2027, and 100,000 RSUs vesting in full on February 13, 2029, subject to performance milestones. On February 13 and 14, 2026, previously granted RSUs vested, resulting in the acquisition of 25,950 shares of common stock through derivative exercises, while 9,004 shares were withheld by the company at $1.89 per share to satisfy tax obligations, which the filing states does not represent an open market sale. After these transactions, Boyle directly owned 298,801 shares of common stock.
C4 Therapeutics, Inc. reported equity compensation and related share movements for Chief Scientific Officer Paige Mahaney. On February 13, 2026, Mahaney received a grant of 240,000 restricted stock units (RSUs). Of these, 120,000 RSUs will vest in three equal annual installments starting on February 13, 2027, and 120,000 RSUs will vest in full on February 13, 2029, with the latter portion subject to performance milestones.
On February 14, 2026, Mahaney acquired 7,050 shares of common stock upon vesting of a previously disclosed RSU grant, and 2,446 shares were withheld by the company to cover tax obligations, which the filing states does not represent a sale. After these transactions, Mahaney directly owned 336,910 shares of common stock.
C4 Therapeutics Chief People Officer Kelly Schick reported several equity compensation transactions in Common Stock. Schick received a grant of 200,000 restricted stock units, with 100,000 vesting in three equal annual installments starting on February 13, 2027 and 100,000 vesting in full on February 13, 2029, subject to performance milestones. Additional shares were acquired through the vesting of previously granted RSUs and by exercising derivative securities, while 7,269 and 1,735 shares were withheld to cover tax obligations, which the company notes do not represent market sales. Following these transactions, Schick directly owned 299,881 shares of Common Stock.
C4 Therapeutics, Inc. reported multiple equity transactions by President & CEO Andrew Hirsch. On February 13, 2026, he received 700,000 restricted stock units (RSUs). According to the disclosure, 350,000 RSUs vest in three equal annual installments beginning on February 13, 2027, and 350,000 RSUs vest in full on February 13, 2029, subject to potential acceleration if certain performance milestones are achieved.
On February 14 and 15, 2026, previously granted RSUs vested, resulting in acquisitions of common stock through derivative exercises and conversions. In connection with these vestings, the company withheld 39,154 and 9,057 shares of common stock at $1.89 per share to cover tax withholding obligations. The filing states these withheld shares do not represent sales by Hirsch. After these transactions, he continued to hold over one million shares directly.